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ABSTRACT
Background: topical antiseptic agents have been used widely in normal skin and wound which is asso-
ciated with side effects such as systemic toxicity.
Objective: Iodine is a non-metallic agent with an antimicrobial property that is used in the clinic as an-
tiseptic. Iodophores such as Povidone-Iodine (PVP-I) introduced to improve the stability of the aqueous 
solution of iodine. Time taking and expensive procedures for producing complex between iodine and 
polyvinyl pyrolidine and systemic iodine absorption after topical PVP-I application are limitations on 
the application of this iodophore. The aim of this study was the design and evaluation of polymeric 
micelles for the overcoming of PVP-I limitations.
Methods: Eight polymeric micelle formulations prepared by the thin-layer method based on full-factori-
al design. In an ex-vivo study permeability of iodine- loaded in polymeric micelles through rat skin was 
evaluated in comparison with PVP-I.
Results: polymeric micelles demonstrated particle size between 14-153 nm that is affected by critical mi-
celle concentration (CMC) and molecular weight of the polymer. Maximum % of drug released after 24 h 
was 62.3% that mainly controlled by the type of polymer. All polymeric micelles significantly decreased 
the percentage of drug permeated through rat skin and so decreased the risk of iodine toxicity. The min-
imum bactericidal concentration of polymeric micelles was comparable with PVP-I.
Conclusion: Polymeric micelle demonstrated a perfect topical carrier for iodine loading and delivery 
through the skin by Iodine entrapment into the skin and sufficiently antimicrobial effect.
Keywords: polymeric micelles; Povidone-Iodine; skin permeation; Iodine toxicity
RESUMEN
Antecedentes: los agentes antisépticos tópicos se han utilizado ampliamente en la piel y heridas nor-
males, lo que se asocia con efectos secundarios como la toxicidad sistémica.
Objetivo: el yodo es un agente no metálico con propiedades antimicrobiana que se usa en la clínica como 
antiséptico. Los yodóforos como la povidona yodada (PVP-I) son introducidos para mejorar la estabili-
dad de la solución acuosa de yodo. El tiempo y el procedimiento costoso para producir complejos entre 
yodo y polivinilpirolidina y la absorción sistémica de yodo después de la aplicación tópica de PVP-I son 
limitaciones en la aplicación de este yodóforo. El objetivo de este estudio fue el diseño y la evaluación de 
micelas poliméricas para superar las limitaciones de PVP-I.
Métodos: Ocho formulaciones de micelas poliméricas son preparadas por el método de capa delgada 
basado en un diseño factorial completo. En un estudio ex vivo, se evaluó la permeabilidad del yodo 
cargado en micelas poliméricas a través de la piel de rata en comparación con PVP-I.
Resultados: las micelas poliméricas demostraron un tamaño de partícula entre 14-153 nm que se ve 
afectado por la concentración crítica de micelas (CMC) y el peso molecular del polímero. El porcentaje 
máximo de fármaco liberado después de 24 h fue del 62,3% que se controla principalmente por el tipo de 
polímero. Todas las micelas poliméricas disminuyeron significativamente el porcentaje de fármaco per-
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meado a través de la piel de rata y, por lo tanto, disminuyeron el 
riesgo de toxicidad por yodo. La concentración bactericida mínima 
de micelas poliméricas fue comparable con PVP-I.
Conclusión: la micela polimérica demostró ser un portador tópico 
perfecto para la carga y entrega de yodo a través de la piel medi-
ante el atrapamiento de yodo en la piel y un efecto antimicrobiano 
suficiente.
Palabras clave: micelas poliméricas, povidona yodada, per-
meación de la piel, toxicidad del yodo
INTRODUCTION
Iodine is a topical effective agent against a wide spectrum 
of bacteria, viruses, fungi, and protozoa(1). Its inherent in-
solubility in water was overcome by alcoholic iodine solu-
tion and Lugol’s Solution containing 5% elemental iodine 
and 10% potassium iodide that was found to be irritating to 
the eyes, skin and mucous membranes. Over the last cen-
tury, scientists have developed a number of iodine prepa-
rations to overcome the adverse side effects of iodine. The 
objective was to avoid such incompatibilities without a sig-
nificant loss of germicidal efficacy. As a result, iodophores, 
such as PVP-Iodine (PVP-I) that acts as a solubilizing agent 
for iodine were developed(2,3).
PVP-I has been widely used on burned skin, mucosa and 
contains a high amount of iodine that can be absorbed(4). 
Systemic iodine absorption is reported even with sin-
gle wound irrigation; therefore repeated usage should be 
avoided in patients with renal impairment(5). Systemic tox-
icity after the application of PVP-I in dogs was reported by 
Glick et al(6). They concluded that during continuous PVP-I 
irrigation, free iodine is absorbed in significant amounts. 
In another study, iododerma was reported following top-
ical PVP-I application(7). Systemic iodine absorption asso-
ciated with the use of preoperative ophthalmic 10% PVP-I 
was reported in 15.5% (8). Hypothyroidism has occurred in 
neonates after PVP-I application and also to the mothers 
during pregnancy or breast feeding(9). In the other study, 
Balin and Pratt showed that dilute solution of PVP-I has a 
toxic effect on human fibroblast and caution should be used 
in the topical application of PVP-I on the open wound and 
prolonged contact with tissue should be avoided(10). Based 
on the above-mentioned studies new iodine carrier should 
be introduced to overcome the adverse side effects of PVP-I 
and limitation of iodine systemic absorption. Polymeric 
micelles (PMs) are self-assembled core-shell nanostructures 
consisting of amphiphilic copolymers(11) that can enhance 
the therapeutic efficacy and minimize the systemic side 
effects of topically applied drugs. A micellar structure is 
formed in an aqueous medium if one segment of the block 
copolymer can provide inter-chain cohesive interactions 
sufficient for the micelle formation(12). Critical features of 
the PMs as drug carriers, including particle size, stability, 
loading capacity and release kinetics of drugs, can be mod-
ulated by the structures and physicochemical properties of 
the constituent block copolymers. Also, nano-engineering 
of block copolymers might allow the preparation of PMs 
with integrated smart functions, such as specific-tissue tar-
get ability, as well as chemical or physical stimuli-sensitiv-
ity. Thus, PMs are nanotechnology-based carrier systems 
that might exert the activity of potent bioactive compounds 
in a site-directed manner, ensuring their effectiveness and 
safety in the clinical use(13).
PMs could enhance the deposition of drugs in targeted sites 
of the skin in the normal and dermatological disorders(14). 
Hydrophobic compounds such as Iodine can be encapsu-
lated in the core of the PM(15). For this purpose, PMs have 
been selected for the localization of iodine into the skin.
MATERIALS AND METHODS
Materials
Iodine was purchased from part Kimia pharmaceutical 
company. Tween 80, span 20, oleic acid, Cholesterol, Polox-
amer 188 and PEG were obtained from Merck (Germany). 
Oleoyl polyoxyl-6 glycerides M 1944 CS (Labrafil) and 
propylene glycol monocaprylate TM 90 (Capryol) were a 
gift from Gattefosse (France). Hydroxyl propyl methyl cel-
lulose (HPMC) (KM4) provided by Aldrich chemical com-
pany Inc. Povidone-Iodine 10% was a gift from Behvazan 
pharmaceutical company (Rasht, Iran). Dialysis bag was 
purchased from Armaghane Kalaye Gavan Company (Teh-
ran, Iran).
Solubility of iodine
The solubility of iodine was determined in different oil 
(oleic acid, isopropyl myristate and paraffin) and surfactant 
(Labrafil, Tween and Span mixture) by dissolving an excess 
amount of iodine in 5ml of oil, and other components using 
a stirrer for 30 minutes at 45°C and then overnight at room 
temperature.
Determination of the critical micelle concentration 
(CMC)
Surfactant and co-surfactant aqueous solutions with differ-
ent concentrations were prepared and the surface tension 
was measured at 25 ºC with a Torsion balance (WHITE 
ELEC Model NO. 83944E). Then the chart of surface ten-
sion versus log concentration was plotted. Critical micelle 
concentration (CMC) calculated based on this plot.
Preparation of iodine polymeric micellar formulation
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Defined amounts of oleic acid and PEG 300 with cholesterol 
mixed together and then chloroform added to this mixture. 
1% iodine dissolved in this mixture and put into a rotary at 
120 rpm and 60 ºC for 15 min to forming uniform lipid film. 
Then 10 ml aqueous solution containing, polymer (HPMC 
or poloxamer), surfactant (labrafil or Tween 80: Span 20 1:1) 
and co-surfactant (capryol) added to uniform lipid film, and 
put the mixture in the sonicator with power 500w at 25 ºC 
and diluted by distilled water to 100 ml. Based on a full-fac-
torial design with three variables on two levels 8 PMs for-
mulation was prepared that their compositions illustrated 
in Table 1. Three independent variables as surfactant type 
(S), polymer type (P) and surfactant/ oil ratio (S/O) were 
used in this study. Two types of surfactants with different 
HLB have been selected for evaluating the effect of HLB on 
micelle stability and Iodine solubility in aqueous solution. 
Labrafil with HLB=4 demonstrates more lipophilic proper-
ty than a mixture of Tween+Span with HLB=7.
Table 1. Different amount of compounds in the PMs (data are presented as w/v %)
formula-
tion Batch 
No
(S/O) 
ratio
S
Poly-
mer
Oleic 
acid
cho-
les-
terol
PEG300
Tween 
80
Span20
capry-
ol
polox-
amer 
188
HPMC
Labra-
fil
1 1 Lab P 0.5 0.3 0.5 - - 0.01 0.1 - 0.8
2 1 Lab h 0.5 0.3 0.5 - - 0.01 - 0.1 0.8
3 1 T+S p 0.5 0.3 0.5 0.4 0.4 0.01 0.1 - -
4 2 Lab p 0.5 0.3 0.5 - - 0.01 0.1 - 1.6
5 2 T+S p 0.5 0.3 0.5 0.8 0.8 0.01 0.1 - -
6 2 Lab h 0.5 0.3 0.5 - - 0.01 - 0.1 1.6
7 1 T+S h 0.5 0.3 0.5 0.4 0.4 0.01 - 0.1 -
8 2 T+S h 0.5 0.3 0.5 0.8 0.8 0.01 - 0.1 -
S/O: surfactant/oil ratio; P: poloxamer; h: HPMC (K4M) ; T: Tween; S: Span
Particle size measurements
Particle size was measured at 25 °C by particle size analyz-
er. The mean droplet size of samples was determined by 
SCATTER SCOPE 1 QUIDIX (South Korea) based on pho-
ton correlation spectroscopy with a wide measurable size 
range (1–7000 nm). Each sample was measured triplicate.
Iodide assay by high-pressure liquid chromatography 
(HPLC) method
Iodide ion (I-) was selected as a major species of iodine 
and determined by the HPLC method consists of the C18 
column (5µm, 25 cm), acetonitrile: 50 mmol/l sodium di-
hydrogen phosphate buffer solution (50:50 v/v) mixture as 
mobile phase, UV-detector at 230 nm.
In-vitro Release study
Franz diffusion cells (area 3.4618 cm2) with a cellulose 
membrane (molecular weight cut off 3000-5000) were uti-
lized to determine the release rate of iodine from different 
PMs formulations. The membrane was then clamped be-
tween the donor and receptor compartments receptor was 
filled with 22ml of distilled water. Iodine-loaded PMs (5cc) 
placed in the donor compartment. At 0.5, 1, 2, 3, 4, 5, 6, 
7, 8 and 24 h time intervals, a 2 ml sample was removed 
from the receptor for iodide determination by HPLC and 
replaced immediately with distilled water.
Animal experiments
Male adult Wistar rats (weighing 150 - 170 g) with ages be-
tween 10 - 12 weeks were purchased from the animal labo-
ratory, Jundishapur University of Medical Sciences, Ahvaz, 
Iran. Animals were kept for 5 days of acclimatization with 
a standard diet and were then treated according to the prin-
ciples for the care and use of laboratory animals. Approval 
for the studies was given by the Ethical Committee of the 
Ahvaz Jundishapur University of Medical Sciences (grant 
number: N-67). The rats were anesthetized with sodium 
thiopental prior to sacrificing them. Abdominal full-thick-
ness skin was removed and any extraneous subcutaneous 
fats cleaned from the dorsal side using cooled pure acetone 
solution.
Skin integrity was evaluated by using an electrical conduc-
tometer at 300 HZ by two stainless steel electrodes. Diffu-
sion cells with a resistance lower than 3.9± 0.15 k Ώ cm-2 
were rejected(16).
In vitro skin permeation studies
The whole skin sample was mounted between the donor 
and receptor compartments of the vertical glass diffusion 
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cells. Iodine-loaded PMs and PVP-I put in the donor com-
partment and the receptor cell was filled with phosphate 
buffer (pH 7) including 0.2% span 20. The diffusion cell was 
placed in a water bath 37 ± 0.5 o C equipped by a magnetic 
stirrer. At predetermined time intervals (0.5, 1, 2, 3,……,8, 
24 h), a 2 ml sample was removed from the receptor and 
immediately replaced with phosphate buffer including 
0.2% span 20 to maintain sink condition. At 24 h, the donor 
solutions were collected in order to calculate the iodide con-
centration. As a control, a blank cell without Iodine-loaded 
PMs and PVP-I were performed as the other cells. The re-
sults were plotted as cumulative permeated drug versus 
time. Based on these plots, the apparent permeability co-
efficient (equation 1) and the steady-state permeation flux 
(Jss) (equation 2) were calculated.
(Eq. 1) 
(Eq. 2)
dQ/dt is the steady-state appearance rate on the acceptor 
side of the skin. A is the area of the skin (cm2) and C0 is the 
initial concentration of the drug in the donor phase. On the 
other hand, % of iodide un-permeated after 24 h (R24%) was 
calculated based on equation 3.
(Eq. 3)
On the other hand, the % of iodide into the skin after 24 h 
(D24%) was calculated by equation 4.
(Eq. 4)
Minimal inhibitory concentration (MIC) of io-
dine-loaded polymeric micelles and PVP-I
The MIC of 1% iodine-loaded PMs and commercial 10% 
PVP-I solution was determined by a microtiter plate using 
Mueller Hinton medium. Appropriate concentrations of the 
sample were prepared and tested against Gram-positive 
Staphylococcus aureus and Gram-negative Pseudomonas 
auroginosa that procured from Persian Type Culture Col-
lection (PTCC), Tehran, Iran. Bacterial suspensions were 
adjusted to 0.08- 0.1 at 600 nm.
Two-fold serial dilution of (Iodine-loaded PMs and PVP-I) 
in Mueller Hinton was carried out to yield different con-
centrations. Equal bacterial inoculum (5µl) was transferred 
to each well and the plate was incubated at 37°C for 12-18 
hours. All wells were evaluated for bacterial growth for the 
determination of MIC. Wells showing no bacterial growth 
were streaked on Mueller Hinton agar and incubated over-
night for Minimal Bactericidal Concentration (MBC).
RESULTS
Solubility study
Among the used oils the oleic acid showed maximum sol-
ubility for iodine and also labrafil as a surfactant demon-
strated high solubility capacity (Table 2). Therefore oleic 
acid was used as an oily phase and Labrafil and mixture of 
Tween 80+Span20 as surfactants.
Table 2. The solubility of iodine in various oils and surfactants 
(M±SD ، n=3)
Component Drug solubility (mg/ml)
Labrafil 233.3±30.5
Oleic acid 80.1±7.8
Isopropyl Myristate 60.5±5.5
Paraffin 10.6±0.8
Tween 80+Span20 (1:1) 125.3±14.5
Critical Micelle Concentration (CMC) determination
Amounts of CMC for surfactant, surfactant with co-sur-
factant and polymer are shown in Table 3. CMC was sen-
sitive to polymer type. So poloxamer can produce micelle 
with the lower concentration that is an advantage for topi-
cal formulation. The result of this study was in accordance 
with the finding reported by Xu in 2013(17). They reported 
that polymers in comparison with surfactant can form mi-
celle with lower CMC and therefore show more stability 
against dilution. But finding in this study demonstrates a 
direct correlation between CMC and the degree of hydro-
phobicity of the polymers. Poloxamer 188 is composed of 
a central hydrophobic chain linked by two hydrophobic 
chains of polyoxyethylene which has HLB around 3(18) . 
HPMC is a non-ionic hydrophilic polymer that forming mi-
celle in higher concentration(19). The CMC of poloxamer is 
affected by other components in the formulation. For exam-
ple, salts and urea Causes decreasing and increasing effects 
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on CMC of poloxamer respectively, and sodium lauryl sul-
fate causes to form mix micelles(20). Therefore in this study 
due to concomitant use of poloxamer with surfactants such 
as Labrafil and mixture of Tween and Span, it is clear that 
CMC will change.
Table 3. Amounts of CMC for surfactant, and surfactant with 
co-surfactant mixture (n/ m2), Mean ± SD, n=3
Formulation components CMC (mg/ml)
Labrafil+capriol 0.07±0.009
Capriol+Span+Twin 0.11±0.008
Poloxamer 0.06±0.006
HPMC 0.8±0.05
PMs characterization
Particle size, percentage of drug released after 24 (DR 24%) 
and iodide content of PMs were calculated and demon-
strated in Table 4.
Table 4. Different characters of PMs (Mean ±SD ، n=5)
Formulation 
No
Particle size 
(nm)
DR24%
Iodide content 
(mg/ml)
1 46.8±7.35 51.1±5.3 0.18±0.02
2 153±6.65 54.5±4.7 0.19±0.02
3 96±0.57 37.5±4.3 0.20±0.02
4 14.2±1.75 50.1±4. 2 0.19±0.02
5 91.3±3.95 38. 9±4.5 0.19±0.02
6 121.3±7.51 58. 7±6.7 0.20±0.02
7 111.1±5.15 64.7±6.3 0.19±0.02
8 134.6±6.64 63.5±5.2 0.19±0.01
PVP-I - - 0.43±0.02
Particle size
The particle size of formulations was between 14.2 to 153 
nm. Regression analysis showed that among the independ-
ent variables, the relationship between polymer type and 
particle size was significant (P = 0.04) in this manner that 
by changing the polymer from HPMC with poloxamer sig-
nificant reduction in particle size occurred.
Iodine content and in vitro drug release
Iodine content in all PMs was less than the PVP-I solution. 
The value of DR 24% is around 37.5 - 64.7. Based on these 
results PMs were prepared by poloxamer demonstrated 
lower values of DR 24% in comparison with HPMC.
It seems that PMs act as a depot for iodine and release it 
slowly. For this reason, iodine content in PMs is lower than 
PVP-I. the chromatogram of iodide in HPLC is presented 
in fig 1.
Figure 1. HPLC chromatogram of Iodide
Permeability study
The drug permeability parameters through rat skin by dif-
ferent formulations and PVP-I are illustrated in table 5. The 
values of Q24 (mg of iodide permeated in 24 h) obtained by 
all PMs were lower than these values obtained by PVP-I. 
This parameter is affected by iodide concentration. Iodide 
concentration in PVP-I is more than iodide concentration 
in PMs. For this reason judgment about the effect of PMs 
based on Q24 is associated with the error. But D 24% is not 
dependent on concentration. Results show PMs 1, 3, 4 and 
5 demonstrated higher D 24% than PVP-I (P-vale<0.05). But 
other PMs indicated lower values of D 24% significantly 
(P-vale<0.05) compared PVP-I. Formulations 1, 3, 4 and 5 
are made by poloxamer as mucoadhesive polymer. Formu-
lation 1 indicated the highest amount of D 24% and cumulat-
ed the highest amount of iodide into the skin. Poloxamer 
with bioadhesive property increased iodine residence time 
into the skin. Only formulations 1, 4 and 5 decreased sig-
nificantly Jss compared with PVP-I that formulation 1 with 
the highest effect indicated 3 folds decrease in Jss.
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Table 5. Different permeability parameters of iodide through rat skin after application of iodine-loaded PMs and PVP-I (Mean ± SD, 
N=5)
Formulation no R24 (mg) Q24(mg) D24% JSS(µg/cm
2.h)
1 0.24 ±0.031 0.19±0.02 52.2±5.8 2.3±0.18
2 0.102±0.002 0.75±0.05 12.62±1.1 9.1±1.01
3 0.18±0.013 0.514±0.06 31.3±3.9 6.2±0.68
4 0.33 ±0.046 0.232±0.03 41.8±4.7 2.8±0.35
5 0.28±0.03 0.431±0.03 24.8±1.83 5.2±0. 50
6 0.12±0.01 0.847±0.093 6.5±0.74 10.2±1.03
7 0.11±0.008 0.714±0.07 13.2±0.95 8.6±0.66
8 0.33±0.041 0.531±0.04 8.2±0.73 6.4±0.68
PVP-I 0.42±0.035 1.73±0.23 19.5±2.3 20.8±3.05
In vitro MIC and MBC of Iodine-loaded PMs and PVP-I
Figure 2. The mean of MIC and MBC of PVP-I and Iodine-loaded 
PMs for two kinds of microorganisms (Mean ± SD, n=6)
The values of MIC and MBC according to PVP-I and Io-
dine-loaded PMs for pseudomonas auroginosa and Staph-
ylococcus aureus are presented in fig. 2. All PMs produced 
MIC against pseudomonas around 7.8-8.4 µg/ml that 
didn’t show a significant difference with PVP-I. This value 
is in accordance with the MIC that previously reported by 
Houang et al(21). The MIC and MBC values provided by all 
PMs against Staphylococcus aureus were comparable with 
PVP-I and are higher than values reported previously(22). 
No significant correlation between independent variables 
and values of MIC and MBC against two microorganisms 
was found. It means that the PMs didn’t alter the activity of 
Iodine against both microorganisms.
DISCUSSION
Toxicity with iodine after application of PVP-I was report-
ed in human. This toxicity, especially after application 
on wound and mucosa, indicated high iodine absorption 
through the skin. The aim of this study was the design 
and evaluation of the capacity of PMs to decrease the rate 
and amount of iodine permeation through the skin. PMs 
demonstrated particle size between 14-153 nm which is af-
fected by the CMC and molecular weight of the polymer. 
PMs with 1% iodine included 0.18-0.210 mg/ml Iodide as 
major species. But PVP-I with 10% iodine consisted of 0.435 
mg/ml iodide. Iodide/iodine ratios for PMs and PVP-I are 
0.018-0.021 and 0.0043, respectively. This contrast indicates 
that more iodide is produced by PMs. Therefore the capac-
ity of PMs for iodine dissolving is more than PVP-I. For 
providing equal available iodine with PVP-I, 1.5% iodine- 
loaded PM solutions should be produced. 3% iodine lipos-
omal formulation that was introduced by another study(23) 
indicated lower iodine potency in compare with PMs that 
introduced in the present study. PMs presented iodine con-
trolled release patterns that mainly affected by the type of 
polymer. Polyethylene oxide chain in poloxamer is respon-
sible for the lipophilic property wich increased iodine af-
finity for loading and lower drug release. PMs significantly 
decreased the values of Jss and Q24 compared to PVP-I. In 
an ex vivo study, Jss of iodine after the application of PVP-I 
through human skin was reported 0.73 µg/cm2.h‏ (4). The 
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reason for higher Jss through rat skin in comparison with 
human skin is the lower barrier property of rat skin. Iodide 
concentration into the skin that is described by D24% deter-
mines antimicrobial efficacy of topically applied antiseptics 
including iodine. Results showed PMs made by poloxamer 
increased D24 % compared PVP-I. Formulation 1 showed 
the best property in iodine localization into the skin and 
reduction in iodine percutaneous absorption. This formu-
lation had the lowest particle size that facilitated iodine 
penetration into the skin. On the other hand simulation 
systems with water-lipid bilayer interface indicated that 
hydrophilic blocks of poloxamers interact with lipid head-
groups and remain at the interface and hydrophobic blocks 
enter into the hydrophobic region of the bilayer(18). These 
simulations for poloxamer micelles next to the lipid bilayer 
showed no permeation of these micelles into the bilayer. 
Therefore poloxamer micelles do not penetrate into the skin 
bilayers and localize iodine on the skin.
CONCLUSION
The aim of this study was to the reduction of iodine per-
meation through the skin. The poloxamer micelles demon-
strated low CMC, small particle size and slow release pro-
file. Poloxamer micelles indicated good iodine loading and 
solubilization properties that decreased iodine dose in the 
micelles. Poloxamer micelles decreased in vitro skin and 
increased iodine skin concentration compared to PVP-I. 
on the other hand, PMs have MIC and MBC values com-
parable with PVP-I. Therefore poloxamer micelles can be 
introduced as appropriate iodine carriers instead of PVP-I.
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